Harmony Biosciences Balance Sheet
NASDAQ: HRMYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Harmony Biosciences financial position
At the end of fiscal 2025, Harmony Biosciences reported total assets of $1.27 billion, up 27.3% from a year earlier against total liabilities of $401.4 million. Shareholders' equity stood at $870.2 million, or 68.4% of assets. The company held $752.5 million in cash and equivalents against $163.7 million of debt, a net cash position of $588.8 million.
The current ratio (current assets divided by current liabilities) was 3.60, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.19.
Summary generated from market data by MetaCap's automated system. Methodology
Harmony Biosciences balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 752.50M | 453.00M | 311.66M | 243.78M | 234.31M | 228.63M | 24.46M |
| Short-Term Investments | 22.84M | 14.19M | 41.80M | 79.33M | — | — | — |
| Receivables | 96.79M | 83.03M | 74.14M | 54.74M | 34.84M | 22.18M | 4.25M |
| Inventory | 5.36M | 7.20M | 5.36M | 4.30M | 4.43M | 3.82M | 1.09M |
| Total Current Assets | 907.01M | 579.25M | 451.07M | 400.29M | 284.44M | 262.89M | 31.50M |
| Property, Plant & Equipment | — | 1.26M | 371.00K | 573.00K | 820.00K | 938.00K | 1.33M |
| Intangible Assets | 89.42M | 113.26M | 137.11M | 160.95M | 143.92M | 162.34M | 72.19M |
| Long-Term Investments | 107.13M | 108.87M | 72.17M | 22.57M | — | — | — |
| Total Assets | 1.27B | 999.20M | 811.45M | 673.87M | 433.44M | 427.07M | 106.70M |
| Accounts Payable | 17.69M | 13.74M | 17.73M | 3.79M | 1.00M | 2.56M | 6.36M |
| Short-Term Debt | 20.00M | 16.25M | 15.00M | 2.00M | 2.00M | — | — |
| Total Current Liabilities | 252.13M | 175.08M | 163.78M | 78.88M | 53.77M | 134.54M | 19.89M |
| Long-Term Debt | 143.66M | 163.02M | 178.57M | 189.65M | 189.98M | 194.25M | 97.95M |
| Total Liabilities | 401.41M | 340.05M | 344.46M | 271.03M | 246.94M | 329.89M | 118.29M |
| Shareholders' Equity | 870.22M | 659.15M | 466.99M | 402.84M | 186.51M | 97.18M | -422.86M |
| Retained Earnings | 160.90M | 2.22M | -143.28M | -272.13M | -453.60M | -488.19M | -422.86M |
| Total Debt | 163.66M | 179.27M | 193.57M | 191.65M | 191.98M | 194.25M | 97.95M |
| Net Cash (Debt) | 611.68M | 287.92M | 159.89M | 131.47M | 42.33M | 34.38M | -73.49M |
| Shares Outstanding | 57.73M | 57.14M | 56.77M | 59.62M | 58.83M | 56.89M | 7.79M |
This table shows 7 annual periods of Harmony Biosciences's balance sheet, from FY 2025 back to FY 2019, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow HRMY's reporting calendar. What is a balance sheet?